Zalcitabine

"Zalcitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

Descriptor ID

D016047

MeSH Number(s)

D03.383.742.680.245.500.950

D13.570.230.329.950

D13.570.230.500.925

D13.570.685.245.500.950

Concept/Terms

Zalcitabine

NSC-606170

Hivid

Below are MeSH descriptors whose meaning is more general than "Zalcitabine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleosides [D03.383.742.680]
Cytidine [D03.383.742.680.245]
Deoxycytidine [D03.383.742.680.245.500]
Zalcitabine [D03.383.742.680.245.500.950]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Deoxycytidine [D13.570.230.329]
Zalcitabine [D13.570.230.329.950]
Dideoxynucleosides [D13.570.230.500]
Zalcitabine [D13.570.230.500.925]
Pyrimidine Nucleosides [D13.570.685]
Cytidine [D13.570.685.245]
Deoxycytidine [D13.570.685.245.500]
Zalcitabine [D13.570.685.245.500.950]

Below are MeSH descriptors whose meaning is related to "Zalcitabine".

Below are MeSH descriptors whose meaning is more specific than "Zalcitabine".

Zalcitabine
Lamivudine

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Zalcitabine" by people in Harvard Catalyst Profiles by year, and whether "Zalcitabine" was a major or minor topic of these publication.

Bar chart showing 33 publications over 14 distinct years, with a maximum of 6 publications in 1995

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	0	1	1
1992	1	0	1
1993	4	0	4
1994	1	0	1
1995	4	2	6
1996	2	2	4
1997	1	3	4
1998	0	3	3
2000	0	3	3
2002	0	1	1
2003	0	1	1
2004	0	1	1
2005	0	2	2
2012	1	0	1

Below are the most recent publications written about "Zalcitabine" by people in Profiles.

Achuthan V, Singh K, DeStefano JJ. Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro. Biochemistry. 2017 Jan 10; 56(1):33-46.

View in: PubMed
Morin B, Whelan SP. Sensitivity of the polymerase of vesicular stomatitis virus to 2' substitutions in the template and nucleotide triphosphate during initiation and elongation. J Biol Chem. 2014 Apr 04; 289(14):9961-9.

View in: PubMed
Patel K, Van Dyke RB, Mittleman MA, Colan SD, Oleske JM, Seage GR. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS. 2012 Oct 23; 26(16):2027-37.

View in: PubMed
Iyer S, Xiao E, Alsayegh K, Eroshenko N, Riggs MJ, Bennett JP, Rao RR. Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors. Gene Ther. 2012 May; 19(5):469-75.

View in: PubMed
Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun; 51(6):2130-5.

View in: PubMed
Baker SG, Fitzmaurice GM, Freedman LS, Kramer BS. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics. 2006 Jan; 7(1):29-40.

View in: PubMed
Sax PE. Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients. AIDS Clin Care. 2005 Jan; 17(1):8.

View in: PubMed
Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004 Apr; 62(1):57-64.

View in: PubMed
Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med. 2004 Jan; 5(1):11-4.

View in: PubMed
Lim SE, Ponamarev MV, Longley MJ, Copeland WC. Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J Mol Biol. 2003 May 23; 329(1):45-57.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Antimicrob Agents Chemother
J Pediatr
AIDS
Proc Natl Acad Sci U S A
N Engl J Med
J Infect Dis
Antiviral Res
AIDS Res Hum Retroviruses
Lancet
J Biol Chem